Table 3 Factors associated with SACT initiation and OS outcomes in patients diagnosed with stage IIIB–IV NSCLC in 2015–2016
Patient characteristics, n (%) | Factors associated with SACT initiationa | Factors associated with OS in SACT-treated patientsb | |||||
|---|---|---|---|---|---|---|---|
Overall | SACT untreated | SACT treated | |||||
Parameter | N = 392 | n = 95 | n = 297 | Adjusted OR (95% CI) | Overall P value | Adjusted HR (95% CI) | Overall P value |
Age at NSCLC diagnosis in years | 0.059 | 0.024 | |||||
< 65 | 190 (48.5) | 36 (37.9) | 154 (51.9) | 1.00 (ref) | 1.00 (ref) | ||
65–74 | 118 (30.1) | 26 (27.4) | 92 (31.0) | 0.85 (0.48–1.52) | 1.42 (1.02–1.96) | ||
≥ 75 | 84 (21.4) | 33 (34.7) | 51 (17.2) | 0.33 (0.18–0.59) | 1.60 (1.09–2.37) | ||
Sex | 0.234 | 0.060 | |||||
Male | 303 (77.3) | 75 (78.9) | 228 (76.8) | 1.00 (ref) | 1.00 (ref) | ||
Female | 89 (22.7) | 20 (21.1) | 69 (23.2) | 1.45 (0.79–2.65) | 0.68 (0.46–1.02) | ||
TNM stage and brain metastasis at diagnosis | 0.001 | < 0.001 | |||||
Stage IIIB | 54 (13.8) | 7 (7.4) | 47 (15.8) | 1.00 (ref) | 1.00 (ref) | ||
Stage IV without brain metastases | 274 (69.9) | 70 (73.7) | 204 (68.7) | 0.41 (0.17–0.99) | 1.49 (0.96–2.33) | ||
Stage IV with brain metastases | 64 (16.3) | 18 (18.9) | 46 (15.5) | 0.29 (0.11–0.81) | 2.93 (1.70–5.07) | ||
Histology and mutations/rearrangements | 0.401 | 0.001 | |||||
NSQ | 289 (73.7) | 68 (71.6) | 221 (74.4) | 1.00 (ref) | – | ||
NSQ EGFR/ALK wildtype | – | – | 147 (49.5) | – | 1.00 (ref) | ||
NSQ EGFR or ALK mutations/rearrangements | – | – | 60 (20.2) | – | 0.68 (0.44–1.06) | ||
NSQ EGFR/ALK not tested | – | – | 14 (4.7) | – | 0.96 (0.46–1.99) | ||
SQ | 83 (21.2) | 20 (21.1) | 63 (21.2) | 0.86 (0.46–1.60) | 1.32 (0.90–1.93) | ||
NSCLC NOS/Others | 20 (5.1) | 7 (7.4) | 13 (4.4) | 0.51 (0.19–1.39) | 3.08 (1.62–5.85) | ||